For blocking antibodies, such as antibodies targeting soluble cytokines (TNF alpha and IL17A) or some immune checkpoints (CTLA-4, PD-1, PD-L1) which are not tumor-specific, the cytotoxicity brought about by ADCC/ADCP should be avoided. Here, CD274 is linked to neoplasm.